Latest Breaking News On - Refractory multiple myeloma - Page 3 : vimarsana.com

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact: Investor contact: .

United statesRegion flamandeEdmond chanJenni mildonCiltacabtagene autoleucelEuropean commission grants conditional approvalLegend biotech united states incJanssen biotech incDrug administrationAmerican society of clinical oncologyEuropean commissionJanssen cilag internationalChinese company legend biotech to develop investigationalAmerican cancer societyCommittee for orphan medicinal productsJanssen research development

Bispecifics in Multiple Myeloma: Insights on Operational Readiness and Patient Care

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.

United statesKirollos hannaHematology oncology pharmacy associationJanssen biotech incPharmacy timesOncology pharmacy associationAnnual conferenceOperationalizing bispecificsRefractory multiple myelomaJanssen biotech

Peptide-drug Conjugates (PDCs) Market Current Scenario with Future Trends Analysis to 2031

Peptide-drug Conjugates (PDCs) Market Current Scenario with Future Trends Analysis to 2031
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

New zealandUnited statesSouth koreaSouth africaDaiichi sankyoSoricimed biopharmaAsia pacificIpsen pharmaPepgen corporationMidatech pharmaChiasma incTechnology trendsMidatech pharma plcSee campaignTeva pharmaceuticals incPeptidream inc

FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

United kingdomGreat britainBryan campbellBristol myers squibbAl olaa abdallahUs myeloma innovations research collaborativeUniversity of kansasEuropean unionCell therapySafety studyStandard regimensSubjects with relapsedRefractory multiple myelomaClinical associate professorClinical directorHematologic malignancies

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Region flamandeGlasgow cityUnited kingdomJo caersMargotj pontKirsten van hoordeJeevan shettyNadia verbruggenLeticia alserawanNuria martinez cibrianClaire venninSergi betriuJulio delgadoSophie servaisYves beguinRuiz astigarraga